International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

ALZHIMER’S DISEASE PREDICTION USING DEEP LEARNING

Mrs. S. Devibala Assistant Professor[1], Aravind Deepak K[2], Prakash R[3]

UG student, Computer Science and Engineering, RVS Educational Trust’s Group of Institutions, Dindigul – 624 005

ABSTRACT:

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that affects millions of people worldwide. Early detection is critical for managing the disease and providing patients with timely interventions. This study proposes a machine learning-based approach for detecting Alzheimer's disease using a dataset of neuroimaging and clinical data. The dataset includes MRI scans, genetic information, and cognitive test results from a large cohort of individuals with varying stages of Alzheimer's. We explore the effectiveness of several machine learning models, including Random Forests, and Convolutional Neural Networks (CNN), to classify individuals as either having Alzheimer's or being cognitively healthy. The results show that the proposed method achieves high classification accuracy, with CNN-based models outperforming traditional methods in terms of sensitivity and specificity. This approach offers a promising tool for early detection of Alzheimer's disease, contributing to more efficient diagnosis and personalized treatment planning.

Keyword: Alzheimer’s Prediction, Parkison Prediction, Disease accuracy

Introduction:

Alzheimer’s disease (AD) is a chronic, progressive neurodegenerative disorder that primarily affects older adults, leading to memory loss, cognitive decline, and ultimately, loss of independence. It is the most common form of dementia and poses a significant burden on individuals, families, and healthcare systems worldwide. Despite ongoing research, there is currently no cure for Alzheimer's, making early and accurate diagnosis critical for timely interventions, slowing disease progression, and improving patient quality of life

What is the Alzheimer’s Disease?

Alzheimer's disease is a long-term, progressive neurological condition that results in brain cell death and shrinkage. It is the most frequent cause of dementia, resulting in a persistent deterioration of social, behavioral, and cognitive abilities that impairs an individual's capacity for independent living. Usually, the illness starts out with mild confusion and memory loss before developing into a serious cognitive and functional impairment. It is linked to aberrant brain deposits of tau tangles and amyloid-beta plaques, which harm and destroy nerve cells. Although the precise cause is unknown, lifestyle factors, genetics (particularly the APOE ε4 gene), and age all play important roles. Treatments can momentarily alleviate symptoms, but there is no cure. Better care, planning, and research participation are made possible by early diagnosis.

What is the use of Alzheimer’s Prediction?

In order to enable earlier intervention and better management, Alzheimer's prediction is used to identify people who are at risk of developing the disease before severe symptoms appear. By identifying Alzheimer's in its preclinical or mild cognitive impairment (MCI) stages, predictive tools assist patients and physicians in making well-informed decisions regarding care planning, treatment, and lifestyle modifications. Clinical trial enrollment is supported by early prediction, which is essential for testing novel medications and treatments. By differentiating Alzheimer's from other memory-loss-causing disorders, it also lowers the number of incorrect diagnoses. Prediction models are used in research to better understand the onset and progression of diseases. Understanding the risk gives families and caregivers time to make financial, legal, and emotional preparations. In the end, Alzheimer's prediction is essential for postponing the onset of symptoms, enhancing patient outcomes.

Methodology:

A combination of data collection, analysis, and interpretation are used in the Alzheimer's prediction methodology to determine a person's risk of contracting the illness. Usually, it starts with collecting patient data, such as lifestyle factors, genetic markers (like APOE ε4), medical history, and cognitive test results (like MMSE or MoCA). Additionally, biomarker analysis from blood or cerebrospinal fluid and advanced imaging methods (MRI, PET scans) are employed. In order to identify trends linked to the risk or progression of Alzheimer's disease, the gathered data is subsequently examined using statistical techniques or machine learning models. To find enduring shifts or patterns in cognition over time, longitudinal data is frequently used.

Interpreting the data to produce a risk assessment or forecast is the last phase. This methodical approach enhances diagnostics and encourages early detection.

Alzheimer’s afffected by climate changes:

A higher risk and worsening of Alzheimer's disease and other types of dementia are associated with climate change, specifically through rising temperatures and air Higher temperatures have the potential to exacerbate inflammation, speed up protein misfolding, and interfere with brain functions, all of which can lead to the onset of neurodegenerative illnesses like Alzheimer's. Dementia risk has also been linked to air pollution, particularly fine particulate matter. Climate change, particularly rising temperatures and air pollution, is linked to an increased risk and deterioration of Alzheimer's disease and other forms of dementia. Elevated temperatures can accelerate protein misfolding, worsen inflammation, and disrupt brain activity, all of which can contribute to the development of neurodegenerative diseases like Alzheimer's. Additionally, air pollution, especially fine particulate matter, has been associated with dementia risk.

How Does Alzheimer’s Prediction work?

Alzheimer's prediction estimates a person's risk of getting the disease by combining clinical, genetic, cognitive, and imaging data. To find early indicators of Alzheimer's-related brain changes, medical professionals and researchers employ techniques like cognitive tests (such as the MMSE or MoCA), brain imaging (such as MRI or PET scans), and biomarkers from blood or cerebrospinal fluid. Risk assessment is also influenced by genetic factors, such as the presence of the APOE ε4 allele. Large amounts of numerical data can be processed by sophisticated techniques, such as machine learning models, to find patterns that forecast the start or course of the illness. Prediction systems assist in identifying Alzheimer's years before complete symptoms appear, allowing for early treatment, by monitoring changes in memory, behavior, and biological markers over time.

Analog Method:

Traditional, non-digital tools like clinical observation, paper-based cognitive tests, and patient interviews are the foundation of analog methods for Alzheimer's prediction. Doctors use manual, hand-scored standardized tests, such as the Mini-Mental State Examination (MMSE) or Clock Drawing Test, to evaluate memory, language, reasoning, and orientation. Doctors also collect comprehensive patient histories, which include changes in mood, personality, and everyday functioning as reported by the patient or caregivers. Physical examinations and neurological tests aid in ruling out additional reasons for cognitive decline. These analog methods concentrate on long-term trends in cognitive decline and behavioral shifts. Analog prediction is still useful in low-resource environments and acts as a first step toward early detection, even though it is less accurate than digital or imaging-based techniques.

Persistence and Trends Method:

The persistent and trends approach to Alzheimer's prediction entails tracking steady, long-term alterations in behavioral and cognitive abilities. Instead of focusing on short-term problems brought on by stress or illness, this method aims to identify symptoms that last over time, such as ongoing memory loss, confusion, or trouble with everyday tasks. In order to identify slow decline, trends are found through repeated assessments, such as cognitive tests or functional evaluations, carried out over months or years. Clinicians can see trends of decline by monitoring scores on instruments such as the MMSE or MoCA over several visits. Behavioral logs and caregiver reports can also be used to identify symptoms that are getting worse. This technique helps differentiate between early Alzheimer's and normal aging, and it's frequently combined with other diagnostic tools to support treatment planning, early intervention.

Numerical Weather Prediction Method:

The numerical Alzheimer's prediction method calculates the chance of getting the disease using mathematical models and quantitative data. This method entails gathering quantifiable data, including brain volume measurements, cognitive test results, genetic markers (such as the APOE ε4 gene), and biomarker levels in blood or cerebrospinal fluid. To forecast disease risk or progression, these inputs are analyzed using statistical methods like logistic regression or machine learning models like decision trees or neural networks. For instance, a model may calculate an 80% chance of Alzheimer's within five years based on a person's age, MMSE score, and amyloid-beta levels. Numerical approaches can monitor disease trends over time and offer unbiased, data-driven insights.

Objective:

1. Early Detection: To allow for prompt intervention, detect Alzheimer's in its early stages.
2. Personalized Care: Assist in treatment, caregiving, and long-term management planning according to personal risk.
3. Promote Research: Assist in the selection of clinical trial participants and enhance knowledge of the course of disease and the effectiveness of treatments.

Results

The outcomes of Alzheimer's prediction offer important information about a person's risk of getting the illness or how quickly it might advance. These results may include a classification, such as "normal," "mild cognitive impairment," or "likely Alzheimer's," or a risk score, such as a percentage chance of getting Alzheimer's within a given time frame. Certain findings, such as anticipated declines in test scores like the MMSE or MoCA over time, may forecast future cognitive decline. The findings can inform referrals, treatment choices, and monitoring plans in clinical settings. They aid in the identification of clinical trial candidates for research. The results may also show whether certain imaging findings or biomarkers are abnormal. All things considered, prediction results encourage early diagnosis, well-informed planning, and individualized treatment, assisting patients, caregivers, and medical professionals in making prompt.



Fig 1 Block Diagram

Conclusion

In conclusion, the use of machine learning techniques, particularly deep learning models like Convolutional Neural Networks (CNNs), has shown significant promise in improving the early detection and diagnosis of Alzheimer's disease. Recent studies demonstrate that integrating neuroimaging data, such as MRI and PET scans, with clinical and genetic information enhances the accuracy and sensitivity of prediction models. Despite the successes, challenges such as data quality, model complexity, and generalizability to diverse clinical settings remain. Nevertheless, the continuous evolution of machine learning methodologies holds potential for more efficient, personalized treatment strategies, making early diagnosis more accessible and effective.

REFERENCES:

Research Papers:

[1] S. Toumaj, A. Heidari, and R. Shahhosseini, "Applications of deep learning in Alzheimer's disease: a systematic literature review of current trends, methodologies, challenges, innovations, and future directions," *Artificial Intelligence Review*, vol. 58, no. 1, pp. 44, Dec. 2024, doi: 10.1007/s10462-024-11041-5.

[2] J. V. Shanmugam, B. Duraisamy, B. C. Simon, and P. Bhaskaran, "Alzheimer's disease classification using pre-trained deep networks," *Biomedical Signal Processing and Control*, vol. 71, p. 103217, Dec. 2022, doi: 10.1016/j.bspc.2021.103217.

[3] S. Wang et al., "Feed-forward neural network optimized by hybridization of PSO and ABC for abnormal brain detection," *International Journal of Imaging Systems and Technology*, vol. 25, no. 3, pp. 153–164, Sep. 2015, doi: 10.1002/ima.22229.

[4] H. T. Gorji and J. Haddadnia, "A novel method for early diagnosis of Alzheimer's disease based on pseudo Zernike moment from structural MRI," *Neuroscience*, vol. 305, pp. 361–371, Jan. 2015, doi: 10.1016/j.neuroscience.2015.07.043.

[5] D. Jha, J.-I. Kim, and G.-R. Kwon, "Diagnosis of Alzheimer's disease using dual-tree complex wavelet transform, PCA, and feed-forward neural network," *Journal of Healthcare Engineering*, vol. 2017, pp. 1–13, Jan. 2017, doi: 10.1155/2017/7460321.

[6] M. Liu, J. Zhang, E. Adeli, and D. Shen, "Joint classification and regression via deep multi-task multi-channel learning for Alzheimer's disease diagnosis," *IEEE Transactions on Biomedical Engineering*, vol. 66, no. 5, pp. 1195–1206, May 2019, doi: 10.1109/TBME.2018.2882957.

[7] N. Mahendran and D. R. V. P. M., "A deep learning framework with an embedded-based feature selection approach for the early detection of Alzheimer's disease," *Computers in Biology and Medicine*, vol. 141, p. 105056, Dec. 2022, doi: 10.1016/j.compbiomed.2021.105056.

[8] S. L. Warren and A. A. Moustafa, "Functional magnetic resonance imaging, deep learning, and Alzheimer's disease: A systematic review," *Journal of Neuroimaging*, vol. 33, no. 1, pp. 5–18, Jan. 2023, doi: 10.1111/jon.13063.

[9] R. Bae et al., "A case–control clinical trial on a deep learning-based classification system for diagnosis of amyloid-positive Alzheimer's disease," *Psychiatry Investigations*, vol. 20, no. 12, pp. 1195–1202, Dec. 2023, doi: 10.30773/pi.2023.0192.

[10] R. Bakare et al., "Revolutionizing the Alzheimer's disease stage diagnosis through AI-powered approach," *International Journal of Intelligent Systems and Applications in Engineering*, vol. 12, no. 13, pp. 407–416, Dec. 2024, doi: 10.18280/isi.120313.

[11] A. Balasundaram et al., "Hippocampus segmentation-based Alzheimer's disease diagnosis and classification of MRI images," *Arabian Journal for Science and Engineering*, vol. 48, no. 8, pp. 10249–10265, Aug. 2023, doi: 10.1007/s13369-023-07274-5.

[12] R. Bapat et al., "Predicting four-year's Alzheimer's disease onset using longitudinal neurocognitive tests and MRI data using explainable deep convolutional neural networks," *Journal of Alzheimer's Disease*, vol. 97, no. 1, pp. 1–11, Jan. 2023, doi: 10.3233/JAD-220866.

[13] A. Bhandarkar et al., "Deep learning-based computer aided diagnosis of Alzheimer's disease: A snapshot of last 5 years, gaps, and future directions," *Artificial Intelligence Review*, vol. 57, no. 2, pp. 1–62, Feb. 2024, doi: 10.1007/s10462-023-10029-0.

[14] L. Bloch and C. M. Friedrich, "Systematic comparison of 3D deep learning and classical machine learning explanations for Alzheimer's disease detection," *Computational Biology and Medicine*, vol. 170, p. 108029, Jan. 2024, doi: 10.1016/j.compbiomed.2023.108029.

[15] L. Bohn et al., "Machine learning analyses identify multi-modal frailty factors that selectively discriminate four cohorts in the Alzheimer's disease spectrum: A COMPASS-ND study," *BMC Geriatrics*, vol. 23, no. 1, p. 837, Dec. 2023, doi: 10.1186/s12877-023-04050-2.

[16] Y. Chen et al., "Contrastive learning for prediction of Alzheimer's disease using brain ^{18}F-FDG PET," *IEEE Journal of Biomedical and Health Informatics*, vol. 27, no. 4, pp. 1735–1746, Apr. 2023, doi: 10.1109/JBHI.2022.3189042.

[17] W. P. Ching et al., "Transfer learning for Alzheimer's disease diagnosis using EfficientNet-B0 convolutional neural network," *Journal of Advanced Research in Applied Sciences & Engineering Technology*, vol. 35, no. 1, pp. 181–191, Jan. 2024, doi: 10.21307/jaraset-2024-035.

[18] J. Chyr et al., "DOTA: Deep learning optimal transport approach to advance drug repositioning for Alzheimer's disease," *Biomolecules*, vol. 12, no. 2, p. 196, Feb. 2022, doi: 10.3390/biom12020196.

[19] P. D. K. et al., "Deep learning techniques for the effective prediction of Alzheimer's disease: A comprehensive review," *Healthcare*, vol. 10, no. 10, p. 1842, Sep. 2022, doi: 10.3390/healthcare10101842.

[20] A. D. Arya et al., "A systematic review on machine learning and deep learning techniques in the effective diagnosis of Alzheimer's disease," *Brain Informatics*, vol. 10, p. 17, Jul. 2023, doi: 10.1186/s40708-023-00195-7.

[21] M. Dua et al., "A CNN–RNN–LSTM based amalgamation for Alzheimer's disease detection," *Journal of Medical and Biological Engineering*, vol. 40, pp. 688–706, Dec. 2020, doi: 10.1007/s40846-020-00535-0.

[22] Z. Xia et al., "A novel end-to-end hybrid network for Alzheimer's disease detection using 3D CNN and 3D CLSTM," in *Proceedings of the 2020 IEEE 17th International Symposium on Biomedical Imaging (ISBI)*, Iowa City, IA, USA, Apr. 2020, pp. 1–4, doi: 10.1109/ISBI45749.2020.9098362.

[23] J. Wen et al., "Convolutional neural networks for classification of Alzheimer's disease: Overview and reproducible evaluation," *Medical Image Analysis*, vol. 63, p. 101694, Jun. 2020, doi: 10.1016/j.media.2020.101694.

[24] M. Liu et al., "Joint classification and regression via deep multi-task multi-channel learning for Alzheimer's disease diagnosis," *IEEE Transactions on Biomedical Engineering*, vol. 66, no. 5, pp. 1195–1206, May 2019, doi: 10.1109/TBME.2018.2882957.

[25] S. Wang et al., "Feed-forward neural network optimized by hybridization of PSO and ABC for abnormal brain detection," *International Journal of Imaging Systems and Technology*, vol. 25, no. 3, pp. 153–164, Sep. 2015, doi: 10.1002/ima.22229.

[26] D. Jha et al., "Diagnosis of Alzheimer's disease using dual-tree complex wavelet transform, PCA, and feed-forward neural network," *Journal of Healthcare Engineering*, vol. 2017, pp. 1–13, Jan. 2017, doi: 10.1155/2017/7460321.

[27] N. Mahendran and D. R. V. P. M., "A deep learning framework with an embedded-based feature selection approach for the early detection of Alzheimer's disease," *Computers in Biology and Medicine*, vol. 141, p. 105056, Dec. 2022, doi: 10.1016/j.compbiomed.2021.105056.

[28] S. L. Warren and A. A. Moustafa, "Functional magnetic resonance imaging, deep learning, and Alzheimer's disease: A systematic review," *Journal of Neuroimaging*, vol. 33, no. 1, pp. 5–18, Jan. 2023, doi: 10.1111/jon.13063.

[29] R. Bae et al., "A case–control clinical trial on a deep learning-based classification system for diagnosis of amyloid-positive Alzheimer's disease," *Psychiatry Investigations*, vol. 20, no. 12, pp. 1195–1202, Dec. 2023, doi: 10.30773/pi.2023.0192.

[30] R. Bakare et al., "Revolutionizing the Alzheimer's disease stage diagnosis through AI-powered approach," *International Journal of Intelligent*

Systems and Applications in Engineering, vol. 12, no. 13, pp. 407–416, Dec. 2024, doi: 10.18280/isi.120313.

[31] A. Balasundaram et al., "Hippocampus segmentation-based Alzheimer's disease diagnosis and classification of MRI images," *Arabian Journal for Science and Engineering*, vol. 48, no. 8, pp. 10249–10265, Aug. 2023, doi: 10.1007/s13369-023-07274-5.

[32] R. Bapat et al., "Predicting four-year's Alzheimer's disease onset using longitudinal neurocognitive tests and MRI data using explainable deep convolutional neural networks," *Journal of Alzheimer's Disease*, vol. 97, no. 1, pp. 1–11, Jan. 2023, doi: 10.3233/JAD-220866.

[33] L. Bloch and C. M. Friedrich, "Systematic comparison of 3D deep learning and classical machine learning explanations for Alzheimer's disease detection," *Computational Biology and Medicine*, vol. 170, p. 108029, Jan. 2024, doi: 10.1016/j.compbiomed.2023.108029.

[34] L. Bohn et al., "Machine learning analyses identify multi-modal frailty factors that selectively discriminate four cohorts in the Alzheimer's disease spectrum: A COMPASS-ND study," *BMC Geriatrics*, vol. 23, no. 1, p. 837, Dec. 2023, doi: 10.1186/s12877-023-04050-2.

[35] A. D. Arya, S. S. Verma, P. Chakarabarti, T. Chakrabarti, A. A. Elngar, A. M. Kamali, and M. Nami, "A systematic review on machine learning and deep learning techniques in the effective diagnosis of Alzheimer's disease," *Brain Informatics*, vol. 10, p. 17, Jul. 2023, doi: 10.1186/s40708-023-00195-7.

[36] S. Mechti and R. Alroobaea, "Alzheimer's Disease Early Detection Using Machine Learning Techniques," *Research Square*, 2021.

[37] V. S. Vijayalakshmi and M. S. Savita, "Alzheimer's disease detection through machine learning," *Annals of Romanian Society of Cell Biology*, vol. 25, no. 3, pp. 2782–2792, 2021.

[38] M. Q. Yang and Q. Li, "Comparison of machine learning approaches for enhancing Alzheimer's disease classification," *PeerJ*, vol. 9, p. e10613, 2021, doi: 10.7717/peerj.10613.